Insider Selling: Seer (NASDAQ:SEER) CFO Sells $14,837.27 in Stock

Key Points

• Seer CFO David Horn sold 7,309 shares at an average price of $2.03, generating $14,837.27 and reducing his ownership by 1.48% to 486,650 shares.
• SEER shares rose 1.5% to $2.05, but the company reported a quarterly loss of $0.31 per share and revenue of $3.10 million, missing analyst estimates for both.
• Institutional investors own 75.2% of Seer, while analysts maintain a consensus “Buy” rating with an average price target of $4.00, despite one firm’s “Sell” rating.

Seer, Inc. (NASDAQ:SEER - Get Free Report) CFO David Horn sold 7,309 shares of the firm's stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $2.03, for a total transaction of $14,837.27. Following the sale, the chief financial officer owned 486,650 shares in the company, valued at $987,899.50. The trade was a 1.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Seer Stock Up 1.5%

SEER stock traded up $0.03 during midday trading on Wednesday, hitting $2.05. The company's stock had a trading volume of 182,540 shares, compared to its average volume of 632,272. Seer, Inc. has a 12 month low of $1.55 and a 12 month high of $2.41. The company has a 50 day moving average of $1.97 and a two-hundred day moving average of $1.88. The firm has a market capitalization of $112.71 million, a price-to-earnings ratio of -1.68 and a beta of 1.55.

Seer (NASDAQ:SEER - Get Free Report) last issued its earnings results on Tuesday, August 11th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.04). Seer had a negative return on equity of 27.23% and a negative net margin of 478.05%.The firm had revenue of $3.10 million during the quarter, compared to the consensus estimate of $3.55 million.

Institutional Investors Weigh In On Seer

Hedge funds and other institutional investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. raised its stake in Seer by 51.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 170,897 shares of the company's stock worth $289,000 after acquiring an additional 58,173 shares during the last quarter. Jane Street Group LLC increased its holdings in shares of Seer by 33.3% in the first quarter. Jane Street Group LLC now owns 254,174 shares of the company's stock valued at $430,000 after purchasing an additional 63,432 shares during the period. Geode Capital Management LLC raised its stake in shares of Seer by 16.5% in the second quarter. Geode Capital Management LLC now owns 509,727 shares of the company's stock worth $1,091,000 after purchasing an additional 72,265 shares during the last quarter. XTX Topco Ltd purchased a new position in shares of Seer in the second quarter worth about $172,000. Finally, Occudo Quantitative Strategies LP purchased a new position in shares of Seer in the second quarter worth about $25,000. Hedge funds and other institutional investors own 75.20% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on SEER. Weiss Ratings restated a "sell (d-)" rating on shares of Seer in a report on Friday, July 17th. Canaccord Genuity Group initiated coverage on shares of Seer in a research note on Monday, May 4th. They issued a "buy" rating and a $4.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $4.00.

About Seer

Seer, Inc is a life sciences company focused on pioneering next-generation proteomics, the large-scale study of proteins and their functions in complex biological systems. By leveraging proprietary nanoparticle-based technology, Seer's platform enables high-throughput, unbiased protein analysis from biological samples, addressing a critical bottleneck in drug discovery, biomarker research and precision medicine.

The company's flagship Proteograph Product Suite combines engineered nanoparticle assays with advanced mass spectrometry and bioinformatics pipelines to deliver deep proteomic coverage in a scalable workflow.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source